Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Organovo Holdings, Inc. (ONVO)

Add ONVO Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator dshade, grantg2, Big_Money_Upward
Search This Board:
Last Post: 10/24/2014 10:59:36 PM - Followers: 281 - Board type: Free - Posts Today: 0
NYSE now, upgraded from OTC!    

This company is 3D bioprinting. That means working towards printing human organs, using stems cells and such as ink.     


 As of Thu, Jul 11, 2013, ONVO trades on NYSE Amex. 

     Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications.
The company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types.
Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine.
Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development.
Organovo's bioprinting technology can also be developed to create surgical tissues direct therapy.
Organovo leads the way in solving complex medical research problems and building the future of medicine.

ONVO Security Details Share Structure

Shares Outstanding 77,816,787 a/o Mar 16, 2014
Float 50,000,000 a/0 May24,2014
Authorized Shares 150,000,000 a/o May24, 2014

IR and Media Contacts:
Investor Relations Contact:
Media Contact:

Mailing Address:
Organovo, Inc.
6275 Nancy Ridge Drive, Suite 110
San Diego, CA 92121
Phone: 1-858-550-9994

For all the latest company information, details, news, please visit


Organovo's Scientific Founder and Chief Scientific Officer, Dr. Gabor Forgacs
is the Executive and Scientific Director of the Shipley Center for Innovation at Clarkson University and the George H. Vineyard Professor of Biological Physics at the University of Missouri.
He developed Organovo's breakthrough organ printing technology while leading a team of top regenerative medicine scientists from multiple universities, with the backing of a $5MM National Science Foundation Grant.
Professor Forgacs is the author of more than 150 peer reviewed journal articles and the textbook Biological Physics of the Developing Embryo, (with Stuart Newman), published by Cambridge University Press.
He holds a PhD in theoretical physics from the Roland Eotvos University, Budapest Hungary. He moved to the United States in the 1980's from the Institute of Physics of the French Atomic Energy Agency in Saclay to accept a professorship at Clarkson University. 
University of Missouri researcher doing groundbreaking work in regenerative medicine. Here is a video:


Organovo strives to advance regenerative medicine to new heights, by enabling bioprinting tissues and 3-D cellular constructs that were not possible before.
The novel and flexible capabilities of the bioprinting technology allow researchers to generate data faster and more efficiently, thus leading to cutting edge scientific findings, publications, and grants.

Organovo's 3-D NovoGen bioprinting technology allows for the placement of cells in any pattern desired.
First, small building blocks of any shape are created from the desired cell type.
Second, these pre-formed cell aggregates are loaded into a print cartridge that is then attached to the bio-printer.
The bioprinter deposits the cell aggregates one layer at a time, creating multiple stacked 2-D patterns.
A non-invasive gel is placed next to the cell aggregates to hold the desired 3-D shape as each layer is placed in 2-D.

After printing, the cell aggregates retain enough cellular mobility for them to flow into one another, creating a fused tissue construct.
The principles of developmental biology, including cellular self-assembly, allow the final construct to mature into the desired shape and properties.



World class support for NovoGen MMX

The NovoGen MMX Bioprinter™ is supported by our scientific and engineering team.
Every customer receives bioprinter training and access to Organovo's scaffold-free proprietary bioprinting process, which includes cell preparation to tissue maturation.
Additional consultation and application support are available upon request. Organovo's success comes from enabling our customers' success.  

   Organovo Support Chart

NovoGen MMX Bioprinter

    The NovoGen MMX Bioprinter™ is a novel hardware and software platform at the forefront of bioprinting research and development. The NovoGen MMX™ was developed to meet challenges in biological research.
The platform takes primary or other human cells and shapes them into 3D tissue, with tremendous cellular viability and biology that is superior to even an animal model.
The platform is being used by Organovo's Pharma partners today to enable cutting edge research into drug discovery.

By allowing creation of three dimensional biological structures, Organovo creates functional human tissue that is superior to current disease models.
By enabling printing of tissue in a laboratory environment, investigations on the constructs can be integrated into your current analysis methods.

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ONVO News: Current Report Filing (8-k) 10/24/2014 05:20:50 PM
ONVO News: Organovo Inc. Selected As A Finalist In 27th Annual CONNECT Most Innovative New Product Awards 09/30/2014 08:05:00 AM
ONVO News: Statement of Changes in Beneficial Ownership (4) 09/16/2014 07:01:04 PM
ONVO News: Current Report Filing (8-k) 09/15/2014 08:05:43 AM
ONVO News: Current Report Filing (8-k) 09/11/2014 08:05:00 AM
News News Alert: Current Report Filing (8-k) 10/24/2014 05:20:50 PM
#7075  Sticky Note Ebola means money for ONVO, Here's why: Big_Money_Upward 10/13/14 12:55:37 PM
#6278  Sticky Note ONVO news: "Organovo Reports Positive Results from a rayank 06/26/14 10:25:47 AM
#6071  Sticky Note ONVO Kidney news & Profile videos dshade 05/24/14 12:15:04 PM
#7161 rayank 10/24/14 10:59:36 PM
#7160   Actually breast cancer was covered at the conference dshade 10/24/14 07:58:07 PM
#7159   Hahaha you are so funny, love your approach Penger 10/24/14 06:01:00 PM
#7158   8-K out. RandolRocketman 10/24/14 05:52:07 PM
#7157   "Next month, Organovo will launch a contract research HennHouse 10/24/14 02:29:35 PM
#7156   #ebola "entirely new way to study disease" Big_Money_Upward 10/24/14 12:31:01 PM
#7155   They should've started with boobs instead of livers rumper 10/24/14 12:26:03 PM
#7154   Who are 3D Biomatrix? Are they in the 72vett 10/24/14 12:25:50 PM
#7153   Yep. ONVO has major future ahead in many areas. dshade 10/24/14 11:42:06 AM
#7152 stockmama22 10/24/14 11:05:59 AM
#7151   Longs are all up nicely and adding on dips dshade 10/24/14 10:18:32 AM
#7150   Must be a pretty good story with 20% 72vett 10/24/14 09:18:56 AM
#7149   all in your mind only 2014trader 10/24/14 07:40:53 AM
#7148   It's good to see people finally recognize glory RallyTheMarket 10/23/14 09:14:44 PM
#7147   well, well, well, look who's back rallytheknowitall 2014trader 10/23/14 08:45:03 PM
#7146   1.) I don't have any short positions on RallyTheMarket 10/23/14 05:28:45 PM
#7145   I wish. Avg up at 5.50 is cool too. dshade 10/23/14 05:13:32 PM
#7144   Go shorty the floor is the limit. If you kisilati 10/23/14 05:02:44 PM
#7143   Looking for $5.50s. Coming soon to a portfolio RallyTheMarket 10/23/14 04:04:33 PM
#7142   I'm loving this run up! It's like a rocket! RallyTheMarket 10/23/14 04:03:35 PM
#7141   Benghazi talk in ONVO? Oh my, I knew RallyTheMarket 10/23/14 03:59:42 PM
#7140   You got the dip part right RallyTheMarket 10/23/14 03:59:04 PM
#7139   Dip. Add. Keep accumulation going. dshade 10/23/14 03:13:36 PM
#7138   Just wait until the Benghazi Queen is his successor! grantg2 10/23/14 03:05:12 PM
#7137   ha ha, yeah Obama said EVERYONE was going Mister Dude 10/23/14 01:24:46 PM
#7136   Maybe ONVO can help with my $18,912 medicalPlan rumper 10/22/14 04:41:12 PM
#7135   Yep. Just doing what Russell Index does until dshade 10/22/14 03:11:39 PM
#7134   Each little bump up is really getting hammered Alvie 10/22/14 01:38:20 PM
#7133   Homertoeclipper1 10/22/14 12:56:11 PM
#7132   But it's common for small companies to use grantg2 10/22/14 10:46:35 AM
#7131   I'm not a short, bank that. Homertoeclipper1 10/21/14 11:11:53 PM
#7130   And again, we heard same short deceptive nonsense dshade 10/21/14 10:08:47 PM
#7129   Thanks I noticed that also. Homertoeclipper1 10/21/14 05:17:35 PM
#7128   They love to play both sides of the RallyTheMarket 10/21/14 04:26:26 PM
#7127   Just accumulating into 2015, like the Institutions are doing. dshade 10/21/14 03:45:32 PM
#7126   Whoa yeah... Homertoeclipper1 10/21/14 03:25:51 PM
#7125   Whoa nothing... grantg2 10/21/14 02:30:46 PM
#7124   I would say watch the latest presentation from http://retailinvestorconferences. heuristictrades 10/21/14 01:25:18 PM
#7123   Whoa Cowboy!, relax... Homertoeclipper1 10/21/14 01:22:15 PM
#7122   you have 3 moderators here, at least grantg2 10/21/14 12:11:10 PM
#7121   On the contrary, I would expect a better Homertoeclipper1 10/21/14 11:47:31 AM
#7120   I like your questioning attitude, rumper. I don't Hello Operator 10/21/14 11:12:36 AM
#7119   What to expect at official product launch? rumper 10/21/14 10:29:11 AM
#7118   Well aware, I have that link: Homertoeclipper1 10/17/14 04:34:10 PM
#7117   10/14 148 Institutions own about 20% dshade 10/17/14 04:29:42 PM
#7116   If I have that much influence in my Homertoeclipper1 10/17/14 04:07:10 PM
#7115   see what those negative vibes do, slowed our dshade 10/17/14 03:50:21 PM
#7114   Yeah, I think I understand the capabilities (as Homertoeclipper1 10/17/14 02:23:46 PM
#7113   your post 6020. think of last week as dshade 10/17/14 02:14:02 PM
#7112   Funny timing. start as we were breaking 6.30 lol dshade 10/17/14 02:12:07 PM